Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | CLL trial updates from EHA 2022

Peter Hillmen • 10 Jun 2022
EHA 2022
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Venetoclax
FLAIR GAIA/CLL13

Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Apellis Pharmaceuticals, Leeds, UK, talks on the changing landscape of chronic lymphocytic leukemia (CLL). Prof. Hillmen explains that the results of FLAIR (ISRCTN01844152) and GAIA/CLL13 (NCT02950051) trials have clearly demonstrated the superiority of targeted therapy over chemoimmunotherapy and have highlighted the efficacy of therapies combining targeted agents with monoclonal antibodies in patients with CLL. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Peter Hillmen

1:55
Key updates from the interim analysis of the FLAIR trial
Peter Hillmen • 10 Jun 2022
1:19
Acalabrutinib vs ibrutinib in previously untreated high-risk CLL
Peter Hillmen • 10 Jun 2022
1:40
The role of MRD in decision-making in CLL
Peter Hillmen • 10 Jun 2022
0:58
ALPINE: QoL in patients with R/R CLL treated with zanubrutinib vs ibrutinib
Peter Hillmen • 10 Jun 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals